Human vascular smooth muscle responses mediated by alpha 2 mechanisms in vivo and in vitro

Frequency and pattern dependence of adrenergic and purinergic vasoconstriction in rat skeletal muscle arteries

Sympathetic nerves fire in bursts followed by brief periods of quiescence. Periods of quiescence may be a valuable part of coding for different neurotransmitters. We compared adrenergic- and non-adrenergic-mediated vasoconstriction with repeating burst patterns versus constant frequency stimulation. Seventeen rats were killed, and the femoral arteries dissected out and mounted in organ tissue baths at 37 degrees C and pH 7.4. Field stimulation was applied to artery rings from five rats at constant frequencies of 2-6 Hz for 144 impulses. In 12 rats, artery rings were stimulated with two burst pattern protocols consisting of repeating pairs, triplets, quadruplets or sextuplets performed using either 8 or 30 Hz as the instantaneous frequency for a total of 144 impulses. All protocols were repeated with the P2 purinergic antagonist pyridoxal-phosphate-6-azophenyl-2'4'-disulphonic acid (PPADs; 0.42 m) or the alpha(1)-antagonist prazosin (1.59 microM). Tension was decreased by the addition of the P2 antagonist PPADs (P < 0.05). Prazosin abolished tension at all constant frequencies (P < 0.05). P2 and alpha(1)-antagonism decreased tension with 8 and 30 Hz burst pattern field stimulation. However, the magnitude of decrease in tension with prazosin was less with burst patterns compared to the same average constant frequencies (P < 0.05). It appears that P2X receptors and alpha(1)-receptors in the femoral artery are sensitive to frequency and patterns of electrical stimulation.

Idazoxan effects upon contractile activity in the rat aorta are related to alpha adrenoceptors and L-type channels

Idazoxan is an alpha(2) adrenoceptor antagonist and alpha(1)/alpha(2) partial agonist which also blocks imidazoline receptors. Although idazoxan is widely used in pharmacological studies, its intrinsic vasoactive properties could bring about some limitations. Others have shown that in rat aorta contracted by phenylephrine idazoxan induces relaxation and that in rat small arteries it preferentially antagonizes the alpha(1)-mediated response. We further investigated this matter, using the rat aorta and focusing on the endothelium-independent effects and on L-type channels. In our study, idazoxan inhibited the contraction induced by phenylephrine, an effect which was stronger in the presence of endothelium, but did not affect the contractions induced by various other agents (high potassium, angiotensin II, prostaglandin F(2alpha)). This preferential inhibition was attenuated by 10(-4) m, but not by 10(-5) m yohimbine, and also reduced by 10(-2) m tetraethylammonium and blunted by 10(-4) m methoxyverapamil. In concentrations above 10(-5) m idazoxan induced weak contractions of the de-endothelized rings, which were prazosin- and methoxyverapamil-sensitive. Others have suggested that cyclic guanosine monophospate mediates the idazoxan-induced endothelium-dependent relaxation, but this is difficult to reconcile with our findings. Potassium efflux could play some role in the direct relaxing effect of idazoxan. The observed idazoxan effects appear as based on action upon alpha(1) receptors, but a direct interaction with L-type calcium channels could also be taken into consideration.

Dexmedetomidine and haemodynamic responses to acute central hypovolaemia in conscious rabbits

1. Effects of the alpha2-adrenoceptor agonist dexmedetomidine on vasoconstrictor and heart rate (HR) responses to acute central hypovolaemia were studied in eight chronically instrumented rabbits. We compared intravenous (i.v.) and fourth ventricular (V4) dexmedetomidine (0.1-10 microg/kg) and the reversal of effects by the alpha2-adrenoceptor antagonist idazoxan and the opioid agonist alfentanil. 2. Gradual inflation of an inferior vena cava (IVC) cuff reduced cardiac index (CI) by 8%/min, with progressive vasoconstriction and increased HR. In control rabbits, at approximately 40% baseline CI, there was sudden decompensation with failure of vasoconstriction and a fall in mean arterial pressure (MAP). 3. Dexmedetomidine (i.v. and V4) reduced resting MAP and HR and caused an earlier decompensation during central hypovolaemia. Intravenous dexmedetomidine (3 and 10 microg/kg) also reduced the slope of the initial vasoconstrictor response and the maximum HR. 4. The effects of dexmedetomidine were reversed by the antagonist idazoxan, which prevented the decompensation phase. Intravenous alfentanil was also effective in restoring the vasoconstrictor response and delaying decompensation with hypovolaemia after dexmedetomidine. Combining dexmedetomidine with an opioid, such as alfentanil, may provide the benefit of reduced sympathetic tone without increased risk of cardiovascular collapse.

The effectiveness of beta-adrenoceptor stimulation and the contribution of beta 1-adrenoceptors increase from the proximal to the distal part of the canine saphenous vein

The present study was undertaken to characterize beta-adrenoceptors of the canine saphenous vein and their distribution along this vessel. In a first series of experiments, concentration-response curves to isoprenaline and forskolin were compared on strips taken from proximal and distal portions of the vein. The tone of the strip was previously increased by phenylephrine to one of the three levels: about 85, 70 and 55% of the maximum, which corresponds to 3.08 +/- 0.16 and 2.96 +/- 0.17 (n = 6) N.g-1, for proximal and distal strips, respectively. The maximal relaxation to isoprenaline was significantly larger in the distal than in the proximal portion, for responses starting at 85 and 70% of the maximum tone. In contrast, forskolin caused 100% relaxation, both proximally and distally, irrespective of the previous tone. In a second series of experiments, the relaxation to dobutamine and terbutaline was compared in proximal and distal portions after the tone had been elevated by adrenaline, noradrenaline and phenylephrine to about 70% of the maximum. When the tone was increased by adrenaline, the relaxation in response to 2.7 mumol.l-1 dobutamine was larger than that to 2.7 mumol.l-1 terbutaline both in proximal and distal portions, while when it was increased by noradrenaline, the relaxation to terbutaline was larger than that to dobutamine in the proximal portion; in the distal portion, dobutamine and terbutaline were equieffective. When the tone was increased by phenylephrine, dobutamine and terbutaline caused equivalent relaxations proximally, but distally the relaxation to dobutamine was larger than that to terbutaline.(ABSTRACT TRUNCATED AT 250 WORDS)

Evidence for functional alpha 2-adrenoceptors on vascular sympathetic nerve endings in the human forearm

The role of alpha 2-adrenoceptors on vascular sympathetic nerve endings in modulating release of the sympathetic neurotransmitter norepinephrine (NE) in humans was examined by measuring the regional rate of appearance of NE in forearm venous plasma (forearm NE spillover [FSO]) in 32 healthy volunteers during intra-arterial infusion of drugs acting at adrenoceptors or directly on vascular smooth muscle. Simultaneous intra-arterial infusions of tracer amounts of [3H]NE were used to calculate the extraction rate of NE in the forearm. Methoxamine or propranolol with epinephrine (PRO + EPI) was used to stimulate alpha-adrenoceptors, yohimbine was used to inhibit alpha-adrenoceptors, and sodium nitroprusside (NIP) was used to produce increases in forearm blood flow directly. Sympathetic efferent activity was manipulated by systemic intravenous infusions of NIP or trimethaphan. Yohimbine and NIP increased and PRO + EPI and methoxamine decreased NE FSO, without effects on systemic blood pressure, heart rate, or arterial levels of catechols. Changes in FSO were flow dependent; therefore, the slope of the relation between the changes in FSO and forearm blood flow was used to evaluate the effects of each drug on regional sympathoneural activity. During administration of yohimbine, the mean slope of the relation between the change in estimated FSO and the change in forearm blood flow was about four times that of the mean slope during administration of NIP (F = 6.35, p less than 0.05). The slopes of the relations between changes in FSO and forearm blood flow were unaffected by systemic trimethaphan or NIP infusion, indicating that the activity of alpha 2-adrenoceptors was not altered during inhibition or reflexive stimulation of sympathetic outflow. The results suggest that alpha 2-adrenoceptors modulate release of NE from vascular sympathetic nerve endings in humans and that the function of these receptors is unchanged during acute changes in junctional NE concentrations.

Alpha 1- and alpha 2-adrenoceptors at different levels of the canine saphenous vein

Presynaptic alpha2- and postsynaptic alpha1-adrenoceptors were compared at the distal and proximal parts of the dog saphenous vein. The results obtained show that: (1) yohimbine is more effective against postsynaptic responses to phenylephrine distally than proximally. On the contrary, WB-4101 is more effective proximally; (2) phenylephrine increases inositol monophosphate production at both levels, but the increase is more pronounced distally; (3) UK-14, 304 and adrenaline reduce and yohimbine and phentolamine increase the release of 3H-noradrenaline caused by electrical stimulation at both levels. However, while adrenaline as well as the antagonists are equipotent at the two levels, UK-14,304 is more potent distally than proximally. In conclusion, we suggest that: more alpha 1A-adrenoceptors exist distally than proximally; imidazoline sites can exist at the distal level which contribute to the higher potency of UK-14,304 distally.

New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance

The pharmacology, clinical efficacy and safety of new alpha-adrenergic receptor antagonists for the treatment of hypertension was reviewed (Table XIV). Although all these agents block alpha 1 receptors, some of them have additional effects on histamine, serotonin, dopamine, and alpha 2 receptors. These other actions account for the differences in the side effect profiles observed, i.e., increased incidence of central nervous system side effects found with indoramin, ketanserin, and urapidil, as well as for some additional beneficial effects of ketanserin (i.e., antiplatelet aggregation activity). The magnitude of BP reduction observed with antagonists of alpha 1-adrenergic receptors is modest. In most studies, the degree of BP reduction is comparable to that of prazosin, but less than that achieved with thiazide diuretics, beta-receptor antagonists, or methyldopa. Studies on the comparative efficacy and safety of new alpha 1 antagonists with converting enzyme inhibitors or calcium-channel blockers are not available. In general, alpha 1 antagonists produce greater reductions in standing than in supine BP, an effect due to the venodilatory action of these drugs. New alpha 1 antagonists appear to have equal efficacy in black and white hypertensive individuals. Their comparative efficacy and safety in young vs elderly hypertensive individuals requires further investigation. No information about the possible development of tolerance during treatment with new alpha 1 blockers was encountered. The effects of alpha 1 antagonists on HR are variable and depend on how long after the oral dose the measurements were obtained. In most studies, no significant HR changes are noticed for readings obtained 24 hours post dose; whereas tachycardia has been observed at the time of peak hypotension. Since alpha 1 antagonist-induced tachycardia is most likely of reflex nature, i.e., mediated to an increase in sympathetic activity, the increased HR may be associated with increases in myocardial contractility and in myocardial oxygen consumption. Consequently, a 24-hour HR monitoring during treatment with alpha 1 antagonists should be required for evaluation of new agents. The hemodynamic, humoral, and hormonal effects of the newer alpha 1-receptor antagonists are comparable to those of prazosin. The most consistent finding is a reduction in total peripheral resistance associated with either no change or with only small increases in cardiac index. These agents have been shown either not to change or to increase renal blood flow.(ABSTRACT TRUNCATED AT 400 WORDS)

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium

The adhesion of human platelets to monolayers of bovine endothelial cells in culture was studied to determine the role of endothelium-derived nitric oxide in the regulation of platelet adhesion. The adhesion of unstimulated and thrombin-stimulated platelets, washed and labelled with indium-111, was lower in the presence than in the absence of bradykinin or exogenous nitric oxide. The inhibitory action of both bradykinin and nitric oxide was abolished by haemoglobin, but not by aspirin, and was potentiated by superoxide dismutase to a similar degree. It is suggested that the effect of bradykinin is mediated by the release of nitric oxide from the endothelial cells, and that nitric oxide release contributes to the non-adhesive properties of vascular endothelium.

Alpha-adrenergic receptors in human blood vessels

The evidence for the presence of postjunctional alpha 1- and alpha 2-adrenoceptor subtypes in human blood vessels is reviewed. Experiments in healthy subjects are described that show that alpha 1- as well as alpha 2-adrenoceptor mediated vasoconstriction contribute to vascular smooth muscle tone and that adrenaline and noradrenaline have similar affinities for each subtype. In addition, evidence is presented for a preferential intrajunctional location of alpha 1-adrenoceptors and a preferential extrajunctional location of alpha 2-adrenoceptors in human blood vessels. It is concluded that at present postjunctional alpha-adrenoceptors in human blood vessels can be classified as alpha 1 and alpha 2. Despite the fact that both subtypes mediate vasoconstriction, these receptors are likely to subserve different physiological functions.